FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to diagnostics, and can be used for determining risk of disturbed enzymatic activity in placental and foetal development while reducing pyruvate content with underlying aggravated cytomegaloviral infection in third trimester of gestation. For this purpose in peripheral blood of pregnant women cytomegalovirus antibody titre is measured, as well as pyruvate content in placental homogenate, followed by cytophotometry analysis of made histological sections of placenta after a histochemical reaction with subsequent determination of content of pyruvate dehydrogenase, and if the cytomegalovirus antibody titre is 1:1600, reducing content of pyruvate placental homogenate to 0.015±0.002 mmol/l and pyruvate dehydrogenase to 35.0±0.95 standard units, the risk of disturbed enzymatic activity in placental and foetal development.
EFFECT: method enables assessing the risk of impaired functioning of placental and foetal development.
1 cl, 2 dwg
